+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Nervous System Drugs Market Research Reports

GABAA Modulators - Pipeline Insight, 2025 - Product Thumbnail Image

GABAA Modulators - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Narcolepsy - Pipeline Insight, 2025 - Product Thumbnail Image

Narcolepsy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 75 Pages
  • Global
From
Partial Seizure - Pipeline Insight, 2025 - Product Thumbnail Image

Partial Seizure - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Neurofibromatoses - Pipeline Insight, 2025 - Product Thumbnail Image

Neurofibromatoses - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Nrf2 Pathway Activators - Pipeline Insight, 2025 - Product Thumbnail Image

Nrf2 Pathway Activators - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Peripheral Neuropathic Pain-Pipeline Insight, 2025 - Product Thumbnail Image

Peripheral Neuropathic Pain-Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Hypersomnia - Pipeline Insight, 2025 - Product Thumbnail Image

Hypersomnia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Guillain-Barré Syndrome (GBS) - Pipeline Insight, 2025 - Product Thumbnail Image

Guillain-Barré Syndrome (GBS) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Amyloid Protein Blockers - Pipeline Insight, 2025 - Product Thumbnail Image

Amyloid Protein Blockers - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Relapsing-Remitting Multiple Sclerosis - Pipeline Insight, 2025 - Product Thumbnail Image

Relapsing-Remitting Multiple Sclerosis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
X Linked Adrenoleukodystrophy - Pipeline Insight, 2025 - Product Thumbnail Image

X Linked Adrenoleukodystrophy - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 40 Pages
  • Global
From
Usher Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Usher Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Dopamine Receptor Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Dopamine Receptor Antagonists - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Status Epilepticus - Pipeline Insight, 2025 - Product Thumbnail Image

Status Epilepticus - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Plexiform Neurofibroma - Pipeline Insight, 2025 - Product Thumbnail Image

Plexiform Neurofibroma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Medical Marijuana - Cannabidiol - Pipeline Insight, 2025 - Product Thumbnail Image

Medical Marijuana - Cannabidiol - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Sandhoff Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Sandhoff Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Alpha4beta7 Integrin Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Alpha4beta7 Integrin Antagonists - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Krabbe Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Krabbe Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more